A meta-analysis of cytokine-induced killer cells therapy in combination with minimally invasive treatment for hepatocellular carcinoma

Clinics and Research in Hepatology and Gastroenterology

Volumn 38, Issue 5, 2014, Pages 583-591

  Li, Xiaofeng ^a   Dai, Dong ^a   Song, Xiuyu ^a   Liu, Jianjing ^a   Zhu, Lei ^a   Xu, Wengui ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURGERY; CANCER SURVIVAL; CELL THERAPY; CHEMOEMBOLIZATION; CHILL; CLINICAL EFFECTIVENESS; CYTOKINE INDUCED KILLER CELL; FEVER; HUMAN; LIVER CELL CARCINOMA; LONG TERM SURVIVAL; META ANALYSIS; MINIMALLY INVASIVE PROCEDURE; MULTIMODALITY CANCER THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RADIOFREQUENCY ABLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; SURVIVAL RATE; SURVIVAL TIME; TRANSARTERIAL CHEMOEMBOLIZATION; CARCINOMA, HEPATOCELLULAR; LIVER NEOPLASMS;

CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; HUMANS; LIVER NEOPLASMS;

EID: 84912530810     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2014.04.010     Document Type: Article

References (36)

1. Aravalli R.N., Steer C.J., Cressman E.N. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008, 48:2047-2063.
2. Höpfner M., Schuppan D., Scherübl H. Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer. World J Gastroenterol 2008, 14:1-14.
3. Decaens T. Liver transplantation forhepatocellular carcinoma: time for an international consensus. Clin Res Hepatol Gastroenterol 2012, 36:316-318.
4. Avila M.A., Berasain C., Sangro B., Prieto J. New therapies for hepatocellular carcinoma. Oncogene 2006, 25:3866-3884.
5. Ni J.Y., Liu S.S., Xu L.F., Sun H.L., Chen Y.T. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol 2013, 139:653-659.
6. Ni J.Y., Liu S.S., Xu L.F., Sun H.L., Chen Y.T. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013, 19:3872-3882.
7. Yan S.S., Xu D.H., Sun B.C. Combination of radiofrequency ablation with transarterial chemoembolization for hepatocellular carcinoma: a meta-analysis. Dig Dis Sci 2012, 57:3026-3031.
8. Lu Z., Wen F., Guo Q., Liang H., Mao X., Sun H. Radiofrequency ablation plus chemoembolization versus radiofrequency ablation alone for hepatocellular carcinoma: a meta-analysis of randomized controlled trials. Eur J Gastroenterol Hepatol 2013, 25:187-194.
9. Zhao M., Wang J.P., Wu P.H., Zhang F.J., Huang Z.L., Li W., et al. Comparative analysis of TACE alone or plus RFA in the treatment of 167 cases of intermediate and advanced staged primary hepatocellular carcinoma. Zhonghua Yi Xue Za Zhi 2010, 90:2916-2921. [in Chinese].
10. Zhao M., Wang J.P., Pan C.C., Li W., Huang Z.L., Zhang L., et al. CT-guided radiofrequency ablation after with transarterial chemoembolization in treating unresectable hepatocellular carcinoma with long overall survival improvement. Eur J Radiol 2012, 81:2717-2725.
11. Borentain P., Gregoire E., Hardwigsen J., Garcia S., Durieux O., Le Treut Y.P., et al. Liver transplantation in a patient treated by sorafenib forhepatocellularcarcinoma. Clin Res Hepatol Gastroenterol 2011, 35:234-236.
12. Dahmani R., Just P.A., Perret C. The Wnt/β-catenin pathway as a therapeutic target in humanhepatocellularcarcinoma. Clin Res Hepatol Gastroenterol 2011, 35:709-713.
13. Ma Y., Zhang Z., Tang L., Xu Y.C., Xie Z.M., Gu X.F., et al. Cytokine-induced killer cells in the treatment of patients with solid carcinomas: a systematic review and pooled analysis. Cytotherapy 2012, 14:483-493.
14. Ma Y., Xu Y.C., Tang L., Zhang Z., Wang J., Wang H.X. Cytokine-induced killer (CIK) cell therapy for patients with hepatocellular carcinoma: efficacy and safety. Exp Hematol Oncol 2012, 1:11-21.
15. Schmidt-Wolf I.G., Lefterova P., Mehta B.A., Fernandez L.P., Huhn D., Blume K.G., et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993, 21:1673-1679.
16. Linn Y.C., Hui K.M. Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 2010, 2010:435745-435752.
17. Introna M., Borleri G., Conti E., Franceschetti M., Barbui A.M., Broady R., et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica 2007, 92:952-959.
18. Wang F.S., Liu M.X., Zhang B., Shi M., Lei Z.Y., Sun W.B., et al. Anti-tumor activities of human autologous cytokine-induced killer (CIK) cells against hepatocellular carcinoma in vitro and in vivo. World J Gastroenterol 2003, 8:464-468.
19. Weng D.S., Zhou J., Zhou Q.M., Zhao M., Wang Q.J., Huang L.X., et al. Minimally invasive treatment combined with cytokine-induced killer cells therapy lower the short-term recurrence rates of hepatocellular carcinomas. J Immunother 2008, 31:63-71.
20. Takayama T., Sekine T., Makuuchi M., Yamasaki S., Kosuge T., Yamamoto J., et al. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 2000, 356:802-807.
21. Huang Z.M., Li W., Li S., Gao F., Zhou Q.M., Wu F.M., et al. Cytokine-induced killer cells in combination with transcatheter arterial chemoembolization and radiofrequency ablation for hepatocellular carcinoma patients. J Immunother 2013, 36:287-293.
22. Higgins J.P., Altman D.G., Gøtzsche P.C., Jüni P., Moher D., Oxman A.D., et al. The Cochrane Collaboration's tool assessing risk of bias in randomised trials. BMJ 2011, 343:d5928.
23. Review Manager (RevMan) [Computer program]. Version 5. 2 2012, The Nordic Cochrane Centre, The Cochrane Collaboration, Copenhagen.
24. Deng W.J., Chen J.W., Luo Y.J., Xiang G.Y. Efficacy and safety of minimally invasive treatment combined with autologous CIK cells infusion. Ling Nan Xian Dai Ling Chuang Wai Ke 2013, 13:29-31. [in Chinese].
25. Huang L.X., Zhou Q.M., Xia J.C. Minimally invasive treatment combined with autologous CIK cell therapy for primary hepatocellular carcinoma: safety and efficacy. Guang Dong Yi Xue 2007, 28:1466-1468. [in Chinese].
26. Pan C.C., Huang Z.L., Li W., Zhao M., Zhou Q.M., Xia J.C., et al. Serum alpha-fetoprotein measurement in predicting clinical outcome related to autologous cytokine-induced killer cells in patients with hepatocellular carcinoma undergone minimally invasive therapy. Ai Zheng 2010, 29:596-602.
27. Zhao M., Wu P.H., Zeng Y.X., Xia J.C., Zhang F.J., Xian L.J., et al. Cytokine-induced killer cell fusion to lower recurrence of hepatocellular carcinoma after transcatheter arterial chemoembolization sequentially combined with radiofrequency ablation: a randomized trial. Zhonghua Xi Xue Za Zhi 2006, 86:1823-1828. [in Chinese].
28. Wang J.P., Li W., Huang Z.L., Wu P.H., Li X.S., Wei Y.D., et al. Value of CIK in the treatment of TACE combined with RFA for HCC in long-term survival and prognostic analysis. Zhonghua Xi Xue Za Zhi 2012, 92:3062-3066. [in Chinese].
29. Hao M.Z., Lin H.L., Cheng Q., Ye Y.B., Chen Q.Z., Chen M.S. Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: a comparative study. Ai Zheng 2010, 29:182-189.
30. He X.B., Wang J., Hu J.H. CIK cells combined with TACE treatment of primary liver cancer randomized controlled study. Si Chuan Xi Xue 2012, 33:1696-1697. [in Chinese].
31. Hao M.Z., Chen Q., Ye Y.B., Xiao J.R., Lin H.L., Wu H., et al. Transcatheter arterial chemoembolization combined with cytokine-induced killers in treatment of hepatocellular carcinoma. Zhong Guo Zhong Liu Sheng Wu Zhi Liao Za Zhi 2006, 13:303-305. [in Chinese].
32. Zhang Z.N., Xu Y.M., Chen F.X., Gao C.J., Zhang G.L., Ma W.Q., et al. Clinical study on the treatment of advanced hepatocellular carcinoma by CIK cell. Dong Nan Guo Fang Yi Yao 2006, 8:84-87. [in Chinese].
33. Tong L.Q., Zhao H.F., You L.G., Chen G.F., Li X.L., Zhang F., et al. Transarterial chemoembolization combined with autologous cytokine-induced killer cells therapy for primary liver cancer. Zhong Guo Pu Tong Wai Ke Za Zhi 2013, 22:876-879. [in Chinese].
34. Wang X.P., Xu M., Gao H.F., Zhao J.F., Xu K.C. Intraperitoneal perfusion of cytokine-induced killer cells with local hyperthermia for advanced hepatocellular carcinoma. World J Gastroenterol 2013, 19:2956-2962.
35. Hui D., Qiang L., Jian W., Ti Z., Da-Lu K. A randomized, controlled trial of postoperative adjuvant cytokine-induced killer cells immunotherapy after radical resection of hepatocellular carcinoma. Dig Liver Dis 2009, 41:36-41.
36. Hontscha C., Borck Y., Zhou H., Messmer D., Schmidt-Wolf I.G. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol 2011, 137:305-310.